Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

Figures

• 

  Figure 1.. Trends in estimated glomerular filtration rate (eGFR) from 6 months before esaxerenone treatment (Pre 6Mo; pre-treatment period) to baseline (initiation of esaxerenone) to 6 months after esaxerenone (Post 6Mo). (A) In individual patients. (B) Box plots showing the median (horizontal lines) and interquartile range (boxes) of eGFR at each time point with the median value indicated by the horizontal line; whiskers show the range. eGFR decreased significantly during the pre-treatment period (green arrow), but was relatively unchanged during the treatment period (blue arrow). MRA, mineralocorticoid receptor antagonist.

• 

  Figure 2.. Comparison of changes in the estimated glomerular filtration rate (∆eGFR) between the pre-esaxerenone treatment period (Before 6Mo) and the esaxerenone treatment period (After 6Mo). The boxes show the interquartile range, with the median value indicated by the horizontal line; whiskers show the range.